Breaking News: Daraxonrasib Approved for Pancreatic Cancer
Today, the U.S. Food and Drug Administration approved daraxonrasib (Rasonque), a groundbreaking new drug for pancreatic cancer that targets...
Category: New therapeutics
Today, the U.S. Food and Drug Administration approved daraxonrasib (Rasonque), a groundbreaking new drug for pancreatic cancer that targets...
Ovarian cancer is often diagnosed at an advanced stage, but research is reshaping how scientists understand and treat the...
The New Drugs on the Horizon sessions at AACR Annual Meeting 2025 unveiled 12 novel cancer therapeutics and discussed...
Clinical trial results reported at the AACR Annual Meeting 2025 showcased new therapeutic approaches for non-small cell lung cancer....
With a five-year survival rate of only 12.5%, any progress toward new therapeutic approaches for pancreatic cancer is welcomed...
Our immune systems are equipped to recognize and destroy cancer cells—if they can find them, that is. And with...
The AACR Annual Meeting 2023, held April 14-19, commemorated several milestones, including the 25th anniversary of the approval of...
FDA approvals issued in third quarter 2023 included a new treatment for prostate cancer harboring BRCA mutations, two new...